What the business is, and whether it's a good one at a fair price.
Operates two business segments: Speciality Chemicals & Pharma Intermediates and Logistics Services. In FY26 consolidated revenue was Rs 52.71 crore with a 15.96% EBITDA margin and net profit of Rs 5.32 crore. In the quarter ended 31 March 2026 the specialty chemicals segment booked Rs 16.88 crore of revenue and Rs 1.25 crore of EBIT, while Logistics Services contributed Rs 1.46 crore of revenue and Rs 0.29 crore of EBIT. The group consolidates subsidiaries Eiko Scientific Solutions LLP and Eikovivify Logistics and associate Reflux Pharmaceuticals, and in January 2026 took a 31.68% stake in SSM Formulations Private Limited, a WHO-GMP pharmaceutical formulations manufacturer based in Hinganghat Wardha. Raw materials are by far the largest cost at 78.3% of revenue, with capex at 0.0% of revenue in FY26.
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
Not enough history to assess.How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from EIKO LIFESCIENCES LIMITED's filed financials and exchange disclosures
EIKO LIFESCIENCES LIMITED is a Chemicals & Petrochemicals company listed on BSE.
Yes. Over the trailing twelve months EIKO LIFESCIENCES LIMITED reported a net profit of ₹5 Cr on revenue of ₹53 Cr.
Not in the latest reported year — EIKO LIFESCIENCES LIMITED's dividend payout for FY26 was nil.
Effectively yes. It holds ₹9 Cr more cash than debt. Debt stands at 0.07× equity.
On trailing P/E, EIKO LIFESCIENCES LIMITED ranks 23 of 103 in Specialty Chemicals — cheaper than 78% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
On a typical session EIKO LIFESCIENCES LIMITED moves 1.29% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by EIKO LIFESCIENCES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
